Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients

Summary

AMP-007 is a Phase 1/2 study for the treatment of advanced, previously treated multiple myeloma. The first phase of the study is designed to determine a safe dose of imexon that can be given to patients with advanced, previously-treated multiple myeloma. The Phase 2 part of the study is designed to provide additional safety data and to gain an understanding of whether imexon can improve the outcome for patients with multiple myeloma

Timeline

Start

2005-10

Primary completion

2006-07

Completion

2008-01

Drugs

Indications